Dosage changes in patients with long-term botulinum toxin use for laryngeal dystonia

Otolaryngology - Head and Neck Surgery

Volumn 140, Issue 1, 2009, Pages 43-47

  Birkent, Hakan ^a   Maronian, Nicole ^b   Waugh, Patricia ^c   Merati, Albert L ^c   Perkel, David ^c   Hillel, Allen D ^c  

^a GULHANE SCHOOL OF MEDICINE   (Turkey)

^b CASE WESTERN RESERVE UNIVERSITY   (United States)

^c UNIVERSITY OF WASHINGTON SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BOTULINUM TOXIN; BOTULINUM TOXIN A;

ADULT; ARTICLE; DIAGNOSTIC IMAGING; DRUG DOSE REDUCTION; DRUG DOSE TITRATION; DRUG EFFICACY; FEMALE; FOLLOW UP; HUMAN; LARYNX CARTILAGE; LONG TERM CARE; MAJOR CLINICAL STUDY; MALE; MEDICAL RECORD REVIEW; SELF REPORT; SMOOTH MUSCLE; SPASMODIC DYSPHONIA; THYROARYTENOID MUSCLE; TREATMENT RESPONSE;

BOTULINUM TOXINS; DYSTONIA; FEMALE; HUMANS; INJECTIONS, INTRAMUSCULAR; LARYNGEAL DISEASES; LARYNGEAL MUSCLES; MALE; MIDDLE AGED;

EID: 58149101181     PISSN: 01945998     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.otohns.2008.10.033     Document Type: Article

References (22)

1. Blitzer A., Brin M.F., Fahn S., et al. Clinical and laboratory characteristics of focal laryngeal dystonia: study of 110 cases. Laryngoscope 98 (1988) 636-640
2. Hillel A.D. The study of laryngeal muscle activity in normal human subjects and in patients with laryngeal dystonia using multiple fine-wire electromyography. Laryngoscope 111 4 pt 2 suppl 97 (2001) 1-47
3. Blitzer A., Brin M.F., Fahn S., et al. Botulinum toxin (BOTOX) for the treatment of "spastic dysphonia" as part of a trial of toxin injections for the treatment of other cranial dystonias. Laryngoscope 96 (1986) 1300-1301
4. American Academy of Otolaryngology-Head and Neck Surgery. Policy statement: botulinum toxin. Alexandria (VA): American Academy of Otolaryngology-Head and Neck Surgery. Revised April 9, 1997; reaffirmed March 1998:1.
5. Blitzer A., and Sulica L. Botulinum toxin: basic science and clinical uses in otolaryngology. Laryngoscope 111 (2001) 218-226
6. Chang C.Y., Chabot P., and Thomas J.P. Relationship of botulinum dosage to duration of side effects and normal voice in adductor spasmodic dysphonia. Otolaryngol Head Neck Surg 136 (2007) 894-899
7. Holden P.K., Vokes D.E., Taylor M.B., et al. Long-term botulinum toxin dose consistency for treatment of adductor spasmodic dysphonia. Ann Otol Rhinol Laryngol 116 (2007) 891-896
8. Blitzer A., Brin M.F., and Stewart C.F. Botulinum toxin management of spasmodic dysphonia (laryngeal dystonia): a 12-year experience in more than 900 patients. Laryngoscope 108 (1998) 1435-1441
9. Tisch S.H., Brake H.M., Law M., et al. Spasmodic dysphonia: clinical features and effects of botulinum toxin therapy in 169 patients-an Australian experience. J Clin Neurosci 10 (2003) 434-438
10. Smith M.E., and Ford C.N. Resistance to botulinum toxin injections for spasmodic dysphonia. Arch Otolaryngol Head Neck Surg 126 (2000) 533-535
11. Borodic G.E., and Ferrante R. Effects of repeated botulinum toxin injections on orbicularis oculi muscle. J Clin Neuroophthalmol 12 (1992) 121-127
12. Davidson B.J., and Ludlow C.L. Long-term effects of botulinum toxin injections in spasmodic dysphonia. Ann Otol Rhinol Laryngol 105 (1996) 33-42
13. Inagi K., Connor N.P., Schultz E., et al. Muscle fiber-type changes induced by botulinum toxin injection in the rat larynx. Otolaryngol Head Neck Surg 120 (1999) 876-883
14. White C.M., Greensmith L., and Vrbová G. Repeated stimuli for axonal growth causes motoneuron death in adult rats: the effect of botulinum toxin followed by partial denervation. Neuroscience 95 (2000) 1101-1109
15. Giladi N. The mechanism of action of botulinum toxin type A in focal dystonia is most probably through its dual effect on efferent (motor) and afferent pathways at the injected site. J Neurol Sci 152 (1997) 132-135
16. Antonucci F., Rossi C., Gianfranceschi L., et al. Long-distance retrograde effects of botulinum neurotoxin A. J Neurosci 28 (2008) 3689-3696
17. Gilio F., Currà A., Lorenzano C., et al. Effects of botulinum toxin type A on intracortical inhibition in patients with dystonia. Ann Neurol 48 (2000) 20-26
18. Byrnes M.L., Thickbroom G.W., Wilson S.A., et al. The corticomotor representation of upper limb muscles in writer's cramp and changes following botulinum toxin injection. Brain 121 (1998) 977-988
19. Bielamowicz S., and Ludlow C.L. Effects of botulinum toxin on pathophysiology in spasmodic dysphonia. Ann Otol Rhinol Laryngol 109 (2000) 194-203
20. Croes S.A., Baryshnikova L.M., Kaluskar S.S., et al. Acute and long-term effects of botulinum neurotoxin on the function and structure of developing extraocular muscles. Neurobiol Dis 25 (2007) 649-664
21. Brashear A., Hogan P., Wooten-Watts M., et al. Longitudinal assessment of the dose consistency of botulinum toxin type A (BOTOX) for cervical dystonia. Adv Ther 22 (2005) 49-55
22. Echeverría Urabayen A., Fanjul S., Meseguer E., et al. Progression of botulinum toxin type A dosage in craniocervical dystonias. An eight year comparative study. Rev Neurol 38 (2004) 511-513